Pulmonary Denervation for Heart Failure-Related Pulmonary Hypertension.

Pulmonary-artery denervation reduces clinical worsening by nearly 50% in patients with heart failure-related pulmonary hypertension compared to medical therapy alone.

• Why it matters: Pulmonary hypertension caused by left heart disease worsens patient outcomes due to sympathetic overactivation, but effective interventions are limited.
• What they did: A multicenter randomized trial in China enrolled 264 patients, comparing pulmonary-artery denervation plus guideline-directed therapy versus therapy alone, tracking clinical worsening over a median of 338 days.
• The result: Pulmonary-artery denervation significantly lowered the 2-year incidence of clinical worsening from 51.5% to 25.7%, with minimal procedural complications, indicating a promising treatment avenue.